Author Archives: admin


Gene Therapy for Sickle Cell Disease Receives Orphan Drug Designation – Monthly Prescribing Reference

Home News Drugs in the Pipeline

The Food and Drug Administration has granted Orphan Drug designation to ARU-1801 (Aruvant) for the treatment of sickle cell disease.

The investigational gene therapy is expected to increase functioning red blood cells through proprietary technology that inserts a modified fetal hemoglobin gene into autologous stem cells via a lentiviral vector. A phase 1/2 clinical study in 10 individuals with sickle cell disease is currently examining the efficacy and safety of ARU-1801.

For patients suffering from sickle cell disease, we believe the ultimate promise of gene therapy is a one-time cure without the side effect profile of high intensity myeloablative conditioning. We are committed to providing patients with that option and look forward to presenting more data on our Reduced Intensity Conditioning (RIC) approach, said Will Chou, MD, Chief Executive Officer of Aruvant.

Orphan Drug status is granted to new therapies that treat diseases impacting 200,000 individuals in the US.

For more information visit aruvant.com.

Please login or register first to view this content.

LoginRegister

Read the rest here:
Gene Therapy for Sickle Cell Disease Receives Orphan Drug Designation - Monthly Prescribing Reference

High-Definition View of Diabetes-Related Proteins Obtained, Opening the Door to Future Treatments – SciTechDaily

GLP1R visualized in insulin-secreting beta cells at super-resolution. Credit: University of Birmingham

Scientists have examined a key receptor for the first time at high resolution broadening understanding of how it might function, and opening the door to future improvements in treating conditions such as type 2 diabetes.

Glucagon-like peptide-1 receptors (GLP1R) are found on insulin-producing beta cells of the pancreas and neurons in the brain. The receptor encourages the pancreas to release more insulin, stops the liver from producing too much glucose, and reduces appetite. This combination of effects can helps to control blood sugar levels.

As such, GLP1R has become a significant target for the treatment of type 2 diabetes, and a range of drugs are now available that are based on it. But much remains unknown about GLP1R function because its small size makes it difficult to visualize.

An international group of scientists led by experts at the University of Birmingham and the Max Planck Institute for Medical Research, Heidelberg, have now conducted a detailed examination of the receptor in living cells.

Researchers used a number of techniques including synthesis of marker compounds, immunostaining, super-resolution microscopy, as well as in vivo examination of mice. They were able to label GLP1R with their developed fluorescent probes so as to show its location in the cells and its response to signal molecules.

Publishing their findings inNature Communications, the researchers who were partly funded by Diabetes UK note that they now provide a comprehensively tested and unique GLP1R detection toolbox, which has updated our view of this receptor, with implications for the treatment of conditions such as obesity and type 2 diabetes.

GLP1R visualized in insulin-secreting beta cells at super-resolution. Credit: University of Birmingham

David Hodson, Professor of Cellular Metabolism, at the University of Birmingham, commented: Our research allows us to visualize this key receptor in much more detail than before. Think about watching a movie in standard definition versus 4k, thats how big the difference is. We believe this breakthrough will give us a much greater understanding of GLP1R distribution and function. Whilst this will not immediately change treatment for patients, it might influence how we design drugs in the future.

Johannes Broichhagen, Departmental Group Leader of the Max-Planck Institute for Medical Research, commented: Our experiments, made possible by combining expertise in chemistry and cell biology, will improve our understanding of GLP1R in the pancreas and the brain. Our new tools have been used in stem cells and in the living animal to visualize this important receptor, and we provide the first super-resolution characterization of a class B GPCR. Importantly, our results suggest a degree of complexity not readily appreciated with previous approaches.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK commented: The effects of type 2 diabetes are serious and widespread, so finding more effective treatments to help people manage their condition and reduce their risk of its potentially devastating complications is absolutely vital.

Through innovative research like this, we can get to grips with key aspects of type 2 diabetes in unprecedented detail, and blaze a trail towards better treatments.

GLP1R is a member of the so-called G protein-coupled receptors (GPCRs), which play a role in many of the bodys functions. An increased understanding of how they work has greatly affected modern medicine, and today, it is estimated that between one-third and one-half of all marketed drugs act by binding to GPCRs.

Reference: Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics by Julia Ast, Anastasia Arvaniti, Nicholas H.F. Fine, Daniela Nasteska, Fiona B. Ashford, Zania Stamataki, Zsombor Koszegi, Andrea Bacon4 , Ben J. Jones, Maria A. Lucey, Shugo Sasaki, Daniel I. Brierley, Benoit Hastoy, Alejandra Tomas, Giuseppe DAgostino, Frank Reimann, Francis C. Lynn, Christopher A. Reissaus, Amelia K. Linnemann, Elisa DEste, Davide Calebiro, Stefan Trapp, Kai Johnsson, Tom Podewin, Johannes Broichhagen and David J. Hodson, 24 January 2020, Nature Communications.DOI: 10.1038/s41467-020-14309-w

The research was funded by Diabetes UK, Medical Research Council (MRC) and European Research Council (ERC).

Originally posted here:
High-Definition View of Diabetes-Related Proteins Obtained, Opening the Door to Future Treatments - SciTechDaily

Cynata Therapeutics to talk stem cell therapies at Proactive"s CEO Sessions – Proactive Investors Australia

Cynatas managing director Dr Ross Macdonald will present at Proactives CEO Sessions in Sydney on February 3 and Melbourne on February 4.

() is focused on using its proprietary Cymerusplatform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders.

The trademark Cymerus refers to the patented process of generating cell-based products from intermediate cells

At present, Cynata is focused on the production of mesenchymal stem cell (MSC)-based products using the Cymerus technology.

An example of an MSC product is CYP-001, targeting graft-versus-host-disease (GvHD) for which a Phase I clinical trial has been completed.

During 2019, Fujifilm did a licensing deal with Cynata for CYP-001 and GvHD for a US$3 million upfront payment and future payments of up to US$43 million.

Cynata continues to focus on early commercialisation of Cynatas Cymerus MSC products and is in active commercial discussions for numerous therapeutic targets.

During calendar year 2020, Cynata plans tobeprogressing to three Phase II trials in for GvHD (funded by Fujifilm), CLI, and osteoarthritis.

The company also continues to investigate the therapeutic potential in numerous additional target areas.

It is worth noting the Cymerus process has a number of key advantages including being only platform in the world able to produce commercial quantities of MSCs from a single source.

Five companies will present at the Sydney and Melbourne events, including (), () and ().

The Sydney session will also include ().

Register now for the CEO Sessions

Sydney event, Monday, February 3

Melbourne event, Tuesday, February 4

See the article here:
Cynata Therapeutics to talk stem cell therapies at Proactive"s CEO Sessions - Proactive Investors Australia

UAB scientist studies aging through gray hair, says hair could be rejuvenated – AL.com

Gray hair got you down? Scientists may have a cure for that.

Okay, maybe not a cure. But, more information about why youre going gray, and what can be done about it.

Dr. Melissa Harris, an assistant professor at the University of Alabama at Birminghams Department of Biology, has spent the last ten years studying melanocyte stem cells and what happens when they fail.

Harris runs a molecular biology lab at UAB and uses CRISPR gene editing tools, single-cell sequencing studies, and network analysis algorithms. She uses gray hair as a model for aging, because she doesnt always need a microscopeshe can see the state of your melanocyte stem cells right away. If hair is all one color, Harris said, the melanocyte stem cells are healthy; but if there are grays mixed in, something isnt right.

Gray hair isnt always an inevitable part of aging, the university said. Through Harris research, shes learned that age isnt the only reason these cells fail, and now Harris is working with gray-haired mice to show there could be a way to bring the cells- and hair pigments- back to life. Shes doing that by working with a biotech startup to study an experimental compound that appears to restore hair color long-term in those mice.

Harris work applies to autoimmune diseases and to melanoma, but she said her primary goal is to understand why somatic stem cells (those found in muscles, bones, and organs that are responsible for tissue regeneration, immune defense, hair color and more) start to fail as a person ages. Most of those stem cell populations are hard to work with in the lab, Harris said, but melanocyte stem cells are an exception.

Does hair graying cause you to die? Harris said. No, you can watch melanocyte stem cells from birth to the end. But, she added that the same cant be said for cells like hematopoetic stem cells, which pump red blood cells in bone marrow. You cant live long without them, Harris said.

Her research will reveal more about the bodys aging process and the life cycles of those stem cells.

Harris is often known as the gray-hair lady in the lab, but she stresses that her gray hair research has bigger implications. Everyone gets gray hair It is considered a vanity science, she said. I am not an abnormally vain person My lab has picked the model that is the most appropriate method to investigate what happens to stem cells as we age.

The work has earned her a grant from the NIHs National Institute of Aging. A paper published by her lab in 2018 showed that MITF, a certain protein that is the master regulator turning on pigmentation genes also represses the innate immune system, according to UAB. The university said when Harris worked with the MITF-deficient mice with a virus, the melanocyte stem cells suffered and the mice got gray hair. The study was globally recognized, and featured in several publications.

Perhaps, in an individual who is healthy yet predisposed for gray hair, because they produce less MITF, getting an everyday viral infection is just enough to cause the decline of their melanocytes and melanocyte stem cells, leading to premature gray hair, Harris told UAB News.

Harris started working with the biotech startup when she was contacted by them last year. They were developing an experimental compound that would regrow hair, and they wanted to know if she would test it on her mice. Harris said she was skeptical, but she conducted a small trial.

It worked. Harris said when she tests gray-haired mice with the compound, she sees hair color come back.

Some gray hairs could be rejuvenated, the university said, through compounds to stimulate the cells. (Courtesy, UAB)

And we can take these same mice, pluck the hair and when new hairs grow out they retain the higher level of pigmentation, suggesting this is permanent, she said. This compound is reprogramming the stem cells, taking them to a younger state, allowing them to start up again.

Harris and Joseph Palmer, one of her doctoral students, are also studying a theory that the melanocyte stem cells spend most of their time in a dormant state, and that the cells can possibly be stimulated.

(Spanish doctors in a study) suggested that some melanocyte stem cells are retained in gray hairs, Harris said. We thought that once you go gray the stem cells are all lost theres no going back. But presumably they can be reactivated. That study means, according to Harris, there may be therapies to reactive the cells, and the compound shes working with alongside the startup could be a promising way forward, according to UAB.

We have an opportunity with this company to find out what are the potential ways we can fix a broken system, Harris said. Were always looking at whats broken and rarely do we get to go in the other direction, towards tissue rejuvenation. So this is exciting.

See the article here:
UAB scientist studies aging through gray hair, says hair could be rejuvenated - AL.com

Blood drive to honor Franklin child with cancer – Daily Journal

The tiny body seemed consumed by tubes and wires and monitors.

Just one day prior, Stephanie and Cody Smith had learned the terrible truth about why their 18-month-old son, Charlie, had been so sick recently. He had neuroblastoma, a cancer that forms on the nerve endings. Scans revealed cancer was on his kidney, lungs, bone and lymph nodes.

To stem the aggressive cancer, his doctors immediately got to work, putting in catheters, taking bone marrow biopsies and preparing for the start of intense chemotherapy. Charlie lay in his hospital bed eating Cheetos Puffs, his favorite food, and sitting with his parents.

"It was hard when we got the news," Stephanie Smith said. "I tried to be calm and collected; I had to be strong for my baby. But its been hard."

Story continues below gallery

The past two months have come straight out of a nightmare for the Smith family. Since Charlie was diagnosed with Stage IV neuroblastoma in November, each day brings uncertainty.

The Franklin family has spent 49 of the last 60 days at Riley Hospital for Children at IU Health. Charlie has gone through rounds of chemotherapy, suffering through fevers, mouth sores, extreme fatigue and nausea that wracked his small body. His treatment will last over the next 18 months, and will include chemotherapy, stem cell transplants, blood transfusions, radiation and immunotherapy.

But despite everything theyve been through, the Smiths remain resolute that Charlie will get better. They have relied on their faith, and an army of supporters who have stepped forward to help them in their worst time, to get them through.

"It was amazing to see so many people come up and love on us. It has taught us to be generous people; weve always thought we were generous people, but when you see the number of people who care for you and pray for you and support you, its really amazing," Stephanie Smith said.

The Smiths have partnered with Versiti Blood Center of Indiana to host a blood drive in Greenwood Saturday. The Cheering for Charlie event will be held from 6 a.m. to 2 p.m., to help increase blood supplies for patients such as Charlie who rely on transfusions to survive.

Every two seconds, someone needs life-saving blood, whether theyre bravely battling disease like Charlie, undergoing surgery or are victims of trauma," said Duane Brodt, spokesman for Versiti. "People need people since blood cant be manufactured."

For most of his life, Charlie was a happy-go-lucky toddler. He loved to smile and laugh, beaming joy. Where his 3-year-old brother Henry was more of a wild child, Stephanie Smith said, Charlie seemed to always be in a pleasant, good mood.

His parents described him as their "happy baby."

Thats what made his lethargy, lack of appetite and gradual decline in health so concerning.

"He was learning how to walk over the summer, and started getting sick," Stephanie Smith said. "We just thought it was a virus; we didnt think of the worst."

Charlie developed a low-grade fever, wasnt eating well and was falling asleep unexpectedly while playing with toys. He wasnt acting like himself, Stephanie Smith said.

During a visit to his pediatrician, the doctor found a hard area on Charlies abdomen, and recommended doing some blood tests and taking an X-ray. Those tests only led to more questions he had severe range anemia and elevated levels of platelets in his blood. But the doctor didnt have any conclusive answers as to what was causing it.

Stephanie Smith, a nurse at Franciscan Health, started hearing warning bells in her mind. That, combined with a mothers intuition, convinced her that they needed to take Charlie to Riley Hospital for Children. After 12 hours in the emergency room, and dozens of tests, doctors found a large tumor in Charlies abdomen.

"Sometimes, when kids are diagnosed with cancer, they can go home and be in and out of the hospital for treatment, but Charlie was really sick. The tumor was pushing on his kidney, damaging his kidney, so we had to stay in the hospital," Stephanie Smith said.

The pathology lab at Riley Hospital for Children confirmed the tumor was neuroblastoma. The cancer forms in immature nerve endings, often in the adrenal glands located near the kidneys and is most common in children age 5 and under, according to the American Cancer Society.

But the cancer is very rare; only about 800 new cases are diagnosed in the U.S. each year, according to the American Cancer Society.

Neuroblastomas grow and spread very rapidly, so treatment would have to be aggressive, doctors explained to the family. Charlies oncologist recommended starting with two rounds of focused chemotherapy, followed by the extraction of his red blood cells for stem cell transplants, then another three rounds of chemotherapy.

Two different stem cell transplants would be held about a month apart, and Charlie would start radiation treatment. Immunotherapy, which jolts the immune system into targeting and killing cancer cells, would be the final part of the regimen.

Almost immediately, Charlie started his chemotherapy.

"It grows so quickly, that we had to be aggressive. The beginning was pretty intense," Stephanie Smith said.

The treatment was hard on Charlies young body. He developed mouth sores and didnt want to eat, and his nausea left him miserable. The Smith family essentially relocated to the hospital, staying with him constantly.

But at the same time, their friends and family, as well as complete strangers, stepped up to offer help. A meal train was set up to provide the family with food, and prayers came from all directions.

A GoFundMe page has raised more than $36,000 for the family. A community Facebook page has more than 5,000 members.

"We had a rally of people come around us," Stephanie Smith said. "We couldnt have done it without all of the people who have come together."

Charlie has completed his first four rounds of chemotherapy, and on Jan. 20, he was able to return home with his family to wait for surgery to remove the tumor in his abdomen. That operation is tentatively going to be early to mid February.

In the meantime, the family has been soaking in the opportunity to be together somewhere besides the hospital. They have also been working to plan the blood drive being held on Saturday.

Charlie has relied on blood transfusions throughout his treatment, and a blood drive would be a way to raise awareness of the importance of those transfusions to cancer patients, Stephanie Smith said.

"Charlie received quite a few blood products, especially early on in his treatment. He had 12 transfusions in these 2 1/2 months. For his little body, thats a lot," she said. "Being a nurse, I didnt realize the number of cancer patients who need blood products. Its so important. So this was a way to let people know that."

Stephanie Smiths sister, Shelby Richards, knew people who had organized drives with their friends and helped the family get the Cheering for Charlie drive going.

The drive is a perfect opportunity to remind people that blood donations are vitally important, Brodt said. Versiti Blood Center of Indiana needs to collect at least 560 blood donations every day to support the need at its 80 hospital partners throughout the state, he said.

"So our Cheering for Charlie will truly make a difference and help save lives," Brodt said.

For the Smith family, the drive is a way to give back for all the love theyve been shown.

"Its really cool for us to see how many people have signed up, and also be advocates for other people who need blood, to just get the word out there about how important it is," Stephanie Smith said. "Its encouraging for us to see people come out to support Charlie and kids like him."

If you go

Cheering for Charlie blood drive

What: A blood drive honoring Charlie Smith, an 18-month-old Franklin child diagnosed with neuroblastoma, a cancer of the nerve cells.

When: 6 a.m. to 2 p.m. Saturday

Where: Versiti Blood Center of Indiana, 8739 U.S. 31 S., Indianapolis

Who can donate: Generally, anyone in good health age 16 and up can donate. Make sure you do not have a cold, flu or sore throat at the time of donation.

How to schedule an appointment: Go to Versiti.org/Indiana

Information: Learn more about Charlie on the Cheering for Charlie! Facebook group page.

Read the original here:
Blood drive to honor Franklin child with cancer - Daily Journal

Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine – MENAFN.COM

(MENAFN - ForPressRelease) 11

New Delhi 23rd January 2020 On Saturday, January 18th, 2020, the Advancells Group & the International Fertility Center together ended their first workshop Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020). The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing & processes and IFC, one of India's most prestigious Fertility institute who were joined by candidates with MBBS/BAMS/BHMS/BPharma & Master's degree in Life Sciences.

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of 'Application of PRP for Skin rejuvenation'; 'Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue'; and 'Cell Culturing and Expansion in a Laboratory', applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, 'Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop'.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), it's hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Advancells Group Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

User :- Ajit Singh

Email :

Mobile:- 9953809503

MENAFN2401202000703206ID1099596615

More:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - MENAFN.COM

Major name scheduled to be in Houston for WWE Royal Rumble PPV – Wrestling News

There have been denials for weeks from Edge about being cleared for in-ring action. He has also been denying that he has plans to wrestle again.

However, I just confirmed with two sources that Edge is scheduled to be in Houston this Sunday night, the site of the Royal Rumble pay-per-view. The source I spoke to did not know what Edge would be doing on the show but it looks likely that he will be a surprise entrant in the Mens Royal Rumble match.

As previously noted, The Wrestling Observer Newsletters Dave Meltzer was the first to report a few months ago that Edge signed a new multi-year deal with WWE. People I spoke with are under the belief that Edge will be wrestling a limited schedule, similar to Brock Lesnar.

PWInsider reported in October that Edge was in Pittsburgh, PA for WWE-related business. WWE files wrestlers out to Dr. Joseph Maroons office in Pittsburgh when they want them to be evaluated for in-ring clearance.

Edge retired in 2011 due to spinal stenosis and it looked like the door was shut for him to ever get physical in a WWE ring again. However, he was brought in for a surprise appearance at the SummerSlam Kickoff show in August to spear Elias.

On his podcast, Edge said that he feels better than he has in years and believed that he could step in the ring again at least for one more match but he did not believe that WWE doctors would clear him. He went on to say that he believed that stem cell treatments could get his neck healthy again within five years. At this point, it looks like he has been cleared for limited action and whatever he does on Sunday should set up his match for WrestleMania in Tampa.

Click here for all of the latest news and rumors on this years Royal Rumble pay-per-view.

See more here:
Major name scheduled to be in Houston for WWE Royal Rumble PPV - Wrestling News

How will technology shape and disrupt our health care this decade? – Times Union

Technology has always been able to revolutionize industry and inspire new possibilities. But in health care, the implications feel much grander. New technologies can be not just life-changing, but literally life-giving.

Progress in the last decade, for example, gave doctors the ability to target disease more precisely than ever before, and to personalize treatment based on an individuals unique genetic profile. Biotechnology, or technology that harnesses the power of living organisms, gave us new therapies to treat cancer and rare diseases, whose sufferers have long felt ignored by health researchers.

Even the less-grand stuff like watches that track your sleep cycles and apps that save you unnecessary trips to the emergency room have exciting implications for the future of health care.

As we turn the page on a new decade, the Times Union asked experts to predict the ways in which technology will help us cross new frontiers in science, health and medicine.

Telemedicine

The use of virtual technology to deliver health care has grown exponentially as providers realize that much of what they do such as triage, examinations, treatment and counseling can be done just as well over a screen.

And while some people prefer to get their care face to face, its just not feasible for everyone. Nor is it cost-effective.

Everyone is looking for more value out of health care, said Keith Algozzine, founder of United Concierge Medicine (UCM), a virtual emergency room service based in Troy. Whether you think the quality isnt what it should be or cost is too high or access or convenience to care isnt ideal, telemedicine can help all of those things.

Employers are flocking to Algozzines UCM service, whose emphasis on triage means people dont wind up at the emergency room for chest pain thats really heartburn or an infection that requires a simple prescription antibiotic.

Getting patients the right care at the right place at the right time tends to save money, said Algozzine, whose company has seen 100 percent year-over-year revenue growth since its founding in 2014.

So where is the next frontier in telemedicine? Algozzine believes theres untapped potential in the world of follow-up care.

Yes, if you need surgery you need to go in and physically see a surgeon, he said. Thats never going to happen virtually. But why do you need to drive back in for routine follow-ups when you can do it using this technology? Follow-up done this way can be done at a fraction of the cost, for a fraction of the time.

Regenerative medicine

If youve ever heard of stem cells, designer cells, or CAR-T therapy, then youve heard of regenerative medicine.

The branch of medicine that involves regrowing, repairing or replacing damaged and diseased organs and cells was worth $28 billion in 2018 and is expected to grow to over $81 billion globally by 2023, experts predict.

Part of the reason is the ongoing success of clinical trials in this area. Stem cell therapy which relies on cells that ultimately develop into blood, bone and brain cells, among other cell types has been effective at treating patients with cancer and blood disorders.

The other reason is its potential to treat a whole host of conditions and diseases.

Essentially what is happening is youre producing tissue at the same rate that it would be produced by the body, at best, said Deepak Vashishth, director of Rensselaer Polytechnic Institutes Center for Biotechnology and Interdisciplinary Studies.

But Vashishth believes scientists can take it one step further.

People are copying or mimicking what nature already does, but what if we could beat nature in some ways and do it faster?

He used the example of a professional football player whos forced out of play by a fractured bone.

Bone will take two to three months to regenerate itself and for a fracture to heal, he said. What if we can make it heal in a month? That would be transformative in terms of health care costs. In regenerative medicine, that concept has not yet been applied.

Smart buildings

The concept of a self-monitoring, self-regulating smart home is not new. In fact, plenty such homes already exist, allowing owners to turn off the coffee pot or adjust the temperature while away at the office or headed out on vacation.

The potential for reduced energy waste has driven a lot of recent growth in the field. But Vashishth believes buildings of the future could be built to monitor and even regulate their occupants health.

Think of an office building where your body temperature is constantly being monitored as you move around. If there is flu going around, it will detect that raised body temperature. It could know before you know.

A less pleasant to think about, but still practical application involves smart toilets. Equipped with sensors and artificial intelligence systems, a toilet could measure your urine flow and test for blood, protein and other indicators that might identify an infection or medical condition early on, he said.

Such toilets are currently in development in some parts of the world.

Your environment need not be passive, either. Aside from monitoring, buildings could be equipped with technology or biomaterials that help regulate your health, as well, Vashishth said.

In 2014, for example, RPI unveiled itsfirst public-scale prototype of a special green wall, featuring large panels of densely packed plants that could improve air quality by enhancing the air filtration that naturally occurs in plants.

Its the kind of interdisciplinary work the intersection of science and architecture that RPI is increasingly known for.

Fundamentally these things could change how we live, Vashishth said. And then the question becomes, once we dont have to care so much about our health, what can we do with our lives?

See the original post:
How will technology shape and disrupt our health care this decade? - Times Union

LifeCell launches ‘Genome-Scope’ newborn genetic testing to diagnose over 4000 genetic conditions – Yahoo India News

Chennai (Tamil Nadu) [India], Jan 24 (ANI/PRNewswire): LifeCell International, India's premier stem cell bank and diagnostics company, today announced the introduction of 'Genome-Scope' - a premier Genetic Diagnostic Test for newborns which assesses for thousands of early childhood-onset disorders.

Notably, LifeCell offers this service within a turnaround time of just ten days, which is twice as fast compared to the nearest offering - a vital time reduction for those who seek urgent diagnosis such as babies in the NICU.

With over 7,000 rare disorders identified so far, it's vastly difficult for doctors to diagnose the same with traditional diagnostic techniques. A recent study showcased that it takes more than seven physicians and four years to diagnose such rare disorders. Misdiagnosis, hidden symptoms and lack of awareness, are the core reasons for the long diagnostic journey of children with genetic disorders.

With more than 80 per cent of them being genetic in nature, the recent emergence of low-cost genome sequencing it's now possible to detect relevant causative mutations of almost all of these conditions within a single test, thus far exceeding the routine newborn screening tests currently being offered which cover at most 50 conditions.

LifeCell has introduced this test under the brand 'Genome-Scope'. This breakthrough test uses advanced next-gen DNA sequencing technology to assess over 4,000 genes related to early childhood-onset disorders, to provide results with more than 95 per cent accuracy within just ten days.

Thus, it has the potential to not only expedite the diagnostic journey but also, to save lives. While not all conditions detected may have treatment, the parents may seek such information as it may help prepare for the care of the baby and also in future family planning.

Genome-Scope is also available for well-born kids to identify predisposition to genetic conditions that if detected late could cause irreparable harm. It also provides information on how and which medications the child would respond to, thus providing an impetus to the practice of personalised medicine.

Genome-Scope will serve as a particularly important tool for those parents with a family history of a genetic disease or those who have previously lost a child to one. However, there is also data suggesting that 80 per cent of babies with genetic diseases are born to parents with no family history or symptoms implying the importance of this test to all families.

The test is conducted through a simple process on the cord blood obtained from the baby right after birth for the extraction and preservation of umbilical cord blood stem cells. Alternatively, the test could also be done with blood samples obtained from the child after birth through heel prick.

The test results are shared with the physician within 10 business days for their reference. Lifecell's in-house certified genetic counsellors would assist the clients in pre and post-test counselling. The raw data is also stored with LifeCell for future re-analysis in case there are any changes in the clinical status of the baby.

"Genome-Scope is yet another milestone in our journey towards providing healthy diagnostic solutions for every stage of the parenthood journey. With Genome-Scope we hope to assist every parent wanting to ensure timely detection of hidden genetic conditions in their newborn that could otherwise go unnoticed," said Ishaan Khanna, Chief Executive Officer - BioBank and Diagnostics, LifeCell.

"We are also glad that our clients who chose to bank their baby's stem cells with us can now benefit from this service since there is no requirement for a separate sample," said Khanna.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

See the original post:
LifeCell launches 'Genome-Scope' newborn genetic testing to diagnose over 4000 genetic conditions - Yahoo India News

Advancells Group, IFC concluded their three-day workshop on Regenerative Medicine – Yahoo India News

New Delhi [India], Jan 23 (ANI/Business Wire India): On Saturday, January 18 2020, the Advancells Group and the International Fertility Center together ended their first workshop - Sub-Specialty Training in Application of Regenerative Medicine (STAR 2020).

The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing and processes and IFC, one of India's most prestigious Fertility institutes who were joined by candidates with MBBS/BAMS/BHMS/BPharma and Master's degree in Life Sciences.

The key-note speaker of the workshop was Dr Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event.

Participants also had a privilege to listen to Dr Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual and kit-based models to help the candidates gain exposure.

Dr Punit Prabha, Head of Clinical Research and Dr Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist.

With the help of detailed analysis of 'Application of PRP for Skin rejuvenation'; 'Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue'; and 'Cell Culturing and Expansion in a Laboratory', applicants understood the application of stem cells in aesthetics, cosmetology, and anti-ageing.

"Educating young scientists about stem cells is important for us. With this workshop, we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers," said Vipul Jain, founder and CEO of Advancells Group.

"We wanted to establish a more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop," he added.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (STAR 2020), it's hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article. (ANI/BusinessWire India)

The rest is here:
Advancells Group, IFC concluded their three-day workshop on Regenerative Medicine - Yahoo India News